AstraZeneca says reports of vaccine’s low efficacy among elderly is “completely incorrect”
The pharmaceutical giant AstraZeneca says reports that its Covid-19 vaccine has an extremely low efficacy among the elderly is “completely incorrect.” German newspapers published articles today reporting that the AstraZeneca vaccine, developed in partnership with Oxford University, has an efficacy less than 10% in those over 65 years old.
The economic daily Handelsblatt reported that Berlin estimated the vaccine’s efficacy for those over 65 years old was just 8%. The vaccine is set to be approved by the European Union this week, but the report adds that Berlin does not expect the vaccine will receive a license allowing use for the elderly.
AstraZeneca released a statement saying the reports of the low efficacy rate for adults over 65 is “completely incorrect.”
“In November, we published data in The Lancet demonstrating that older adults showed strong immune responses to the vaccine, with 100% of older adults generating spike-specific antibodies after the second dose.”
Thailand is lined up to receive 50,000 doses of the AstraZeneca vaccine next month and the Thai government has approved the vaccine for emergency use. Public Health Minister Anutin Charnvirakul is now calling on hospitals, both public and private, to prepare for the first phase of vaccinations, starting with health care workers and vulnerable groups in high risk areas. The vaccine requires 2 doses injected 4 to 12 weeks apart.
SOURCES: Reuters | Nation Thailand | AFP
Catch up with the latest daily “Thailand News Today” here on The Thaiger.
